Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tenofovir Alafenamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.50 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenofovir Alafenamide SCHEMBL16280324 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL16402708 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL20456396 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL14440384 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL13155662 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL3107149 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL3107144 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL19467840 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL22139335 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL13964717 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215031-A1 | CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDE | GILEAD SCIENCES, INC. | 2025-07-03 | — | — | US | disclosed |
| US-12202849-B2 | Crystalline forms of tenofovir alafenamide | GILEAD SCIENCES, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| EP-3577125-B1 | CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDE | GILEAD SCIENCES INC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20230091736-A1 | CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDE | GILEAD SCIENCES, INC. | 2023-03-23 | — | — | US | disclosed |
| US-11440928-B2 | Crystalline forms of tenofovir alafenamide | GILEAD SCIENCES, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| EP-3430020-B1 | A PREPARATION METHOD OF DIASTEREOMERICALLY PURE TENOFOVIR ALAFENAMIDE OR ITS SALTS | ZENTIVA KS (CZ) | 2021-07-28 | — | — | EP | disclosed |
| US-20190233448-A1 | CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDE | GILEAD SCIENCES, INC. | 2019-08-01 | — | — | US | disclosed |
| US-10287307-B2 | Crystalline forms of tenofovir alafenamide | GILEAD SCIENCES, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180265530-A1 | CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDE | GILEAD SCIENCES, INC. | 2018-09-20 | — | — | US | disclosed |
| WO-2018144390-A1 | CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDE | GILEAD SCIENCES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215031-A1 | CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDE | HPRT1, SAMHD1, PNP | FAP 249/4885CYP3A4 101/4885CYP2D6 473/4885 |
| US-11440928-B2 | Crystalline forms of tenofovir alafenamide | HPRT1, SAMHD1, PNP | FAP 249/4885CYP3A4 101/4885CYP2D6 473/4885 |
| US-20230091736-A1 | CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDE | HPRT1, SAMHD1, PNP | FAP 249/4885CYP3A4 101/4885CYP2D6 473/4885 |
| US-20190233448-A1 | CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDE | HPRT1, SAMHD1, PNP | FAP 249/4885CYP3A4 101/4885CYP2D6 473/4885 |
| US-10287307-B2 | Crystalline forms of tenofovir alafenamide | HPRT1, SAMHD1, PNP | FAP 249/4885CYP3A4 101/4885CYP2D6 473/4885 |
| US-12202849-B2 | Crystalline forms of tenofovir alafenamide | HPRT1, SAMHD1, PNP | FAP 249/4885CYP3A4 101/4885CYP2D6 473/4885 |
| US-20180265530-A1 | CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDE | HPRT1, SAMHD1, PNP | FAP 249/4885CYP3A4 101/4885CYP2D6 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.